Microbubble enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma
Open Access
- 1 January 2019
- journal article
- Published by Ivyspring International Publisher in Nanotheranostics
- Vol. 3 (4) , 331-341
Abstract
Background and Objective: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy, and its current management relies heavily on locoregional therapy for curative therapy, bridge to transplant, and palliative therapy. Locoregional therapies include ablation and hepatic artery directed therapies such as embolization and radioembolization. In this study we evaluate the feasibility of using novel antivascular ultrasound (AVUS) as a noninvasive locoregional therapy to reduce perfusion in HCC lesions in a rat model and monitor the effect with contrast-enhanced ultrasound imaging.Keywords
This publication has 36 references indexed in Scilit:
- Cancer statistics, 2018CA: A Cancer Journal for Clinicians, 2018
- Current progress in antivascular tumor therapyDrug Discovery Today, 2017
- Remotely Triggered Nano-Theranostics For Cancer ApplicationsNanotheranostics, 2017
- Global Epidemiology of Hepatocellular CarcinomaClinics in Liver Disease, 2015
- Vascularity Assessment of Thyroid Nodules by Quantitative Color Doppler UltrasoundUltrasound in Medicine & Biology, 2015
- Potential chemoprevention of diethylnitrosamine-induced hepatocarcinogenesis in rats: Myrrh (Commiphora molmol) vs. turmeric (Curcuma longa)Acta Histochemica, 2012
- Advances in Ultrasound Mediated Gene Therapy Using Microbubble Contrast AgentsTheranostics, 2012
- Renal Blood Flow Changes Induced with Endothelin-1 and Fenoldopam Mesylate at Quantitative Doppler US: Initial Results in a Canine StudyRadiology, 2001
- Quantitative vascularity of breast masses by Doppler imaging: regional variations and diagnostic implications.Journal of Ultrasound in Medicine, 2000
- Temperature and blood flow studies after ultrasonic irradiation.1955